logo
E.coli can turn plastic into painkillers, chemists discover

E.coli can turn plastic into painkillers, chemists discover

CTV News3 days ago

Scientists say they have found a way to use E.Coli to convert plastic waste into a popular painkiller.
Scientists have found a way to use the bacteria E.Coli to convert plastic waste into a popular painkiller, a study said Monday, though outside experts doubted the technique would make a dent in the fight against plastic pollution.
Paracetamol, which is one of the most commonly used drugs worldwide, is made from the derivatives of fossil fuels, often by Asia-based subcontractors using cheap, polluting methods that contribute to climate change.
The world is also facing an escalating crisis of plastic pollution, with countries set for another bruising round of negotiations in August in the hope of sealing an international treaty to reduce plastic waste.
The British team of researchers behind the new study sought to find a solution to the two problems by roping in a third -- E.coli, which is normally known for making people sick when they eat contaminated food.
First the chemists used a molecule derived from PET plastic, which is used in bottles and many other plastic products the world over, to spark a chemical reaction in a strain of E.coli.
This created a molecule they called PABA, according to the Nature Chemistry study, which was partly funded by drug firm AstraZeneca.
By genetically modifying the bacteria, the chemists were able to transform their molecule into acetaminophen, also known as paracetamol.
'This work demonstrates that PET plastic isn't just waste or a material destined to become more plastic -- it can be transformed by microorganisms into valuable new products, including those with potential for treating disease,' lead study Stephen Wallace said in a statement.
Singaporean researchers not involved in the study praised how it combined synthetic and biological chemistry.
But 'several practical considerations remain' to take this idea beyond the proof-of-concept stage, they wrote in a linked commentary in the journal Nature Chemistry.
The chemical reaction produces only a limited amount of PABA molecules, which 'may be insufficient for industrial applications', they wrote.
Melissa Valliant, communications director of the Beyond Plastics project of Bennington College in the United States, expressed scepticism.
'A new 'plastic-eating bacteria' pops up in the news every few months and has been doing so for years,' she told AFP.
'These discoveries never scale up to anything significant enough to tackle the massive plastic pollution problem.'
This 'crisis needs to be stopped at the source,' she added, which means 'companies and policymakers must reduce the amount of plastic being produced and used in the first place'.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare
Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare

National Post

time2 hours ago

  • National Post

Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare

Article content GENEVA — Six leading international organizations representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry have today adopted the first joint ethical principle in the healthcare industry on the responsible use of health data and technology, including artificial intelligence. Article content The new principle joins the International Consensus Framework for Ethical Collaboration in Health, guiding ethical collaboration across bodies representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry. Article content The new principle joins the International Consensus Framework for Ethical Collaboration (ICF), a longstanding principles-based voluntary agreement that guides ethical collaboration across these major healthcare bodies, working together to deliver high quality care for patients. Article content The ICF was established in 2014 as a global platform to ensure that relationships across the health ecosystem are grounded in ethical, transparent, and responsible decision-making. It unites six leading health bodies representing patient organizations, healthcare professionals, and the pharmaceutical industry. Article content The founding principles of the ICF focus on prioritizing patients; supporting ethical research and innovation; ensuring independence and ethical conduct; and promoting transparency and accountability. Article content The new fifth principle focuses on autonomy, data stewardship, and shared accountability in the use of health data. This reflects the growing importance of digital health and AI, and the need for ethical considerations to evolve alongside scientific innovation. Article content 'No single hospital or stakeholder can navigate today's rapid advances in health data and technology alone,' said Ronald Lavater, CEO of the International Hospital Federation. 'The ICF enables collective action, empowering global health leaders to build trusted partnerships that unlock the full potential of ethical, person-centered innovation.' Article content 'Data and technology may evolve care delivery, but ethics guides our why, how and for whom,' said Howard Catton, CEO of the International Council of Nurses. 'This principle affirms the enduring importance of trust, compassion, and dignity — values nurses uphold every day across health systems worldwide.' Article content Patient voices are central to the adoption of this principle. 'This new principle is a major step forward in safeguarding the rights of patients and people with lived experience in the digital age,' said Dani Mothci, CEO of the International Alliance of Patients' Organizations. 'As a founding member of the ICF, IAPO welcomes the clear ethical commitment around autonomy, data stewardship, and accountability highlighting focus on putting patients first. To make this a reality, we encourage patient organizations to actively engage with this principle and ensure its implementation reflects real-world patient experiences.' Article content 'Ethics is the cornerstone of effective global health policy. It ensures that decisions are guided by fairness, respect, and accountability. The World Medical Association believes that ethical collaboration is essential to building resilient health systems and delivering better care to all, especially the most vulnerable,' said Dr. Ashok Philip, President of the World Medical Association. Article content Paul Sinclair, President of the International Pharmaceutical Federation, called on pharmacy professionals to embrace the new principle: 'FIP supports ethical and responsible decision making, which involves pharmacy practitioners in relation to patients, healthcare professionals, and the pharmaceutical sector to ensure high-quality care. I invite all our members to adopt and adapt this framework at the country and regional levels of practice.' Article content David Reddy, Director General of the International Federation of Pharmaceutical Manufacturers and Associations, echoed the call for collective responsibility: 'For the past decade, the ICF has fostered stronger alliances and shared values between key partners involved in healthcare delivery, through sustained engagement on emerging ethical challenges. Today, by integrating a new principle on digital health and AI, we're echoing a growing consensus: as innovation accelerates, ethical collaboration must evolve in tandem. Our focus is on delivering for patients — first and always.' Article content Established in 2014, the Article content International Consensus Framework for Ethical Collaboration Article content is the only global platform of its kind that brings together patients' organizations, healthcare professionals, and the pharmaceutical industry in support of high-quality, patient-centered care. The Framework is jointly supported by six leading bodies – the Article content , Article content , Article content IFPMA Article content , Article content FIP Article content , Article content WMA Article content , and Article content IHF Article content – all united by a shared commitment to ensuring that relationships across the health ecosystem are grounded in ethical, transparent, and responsible decision-making. The Consensus Framework is a living document and is open to other stakeholders in life sciences and healthcare delivery, who are encouraged to endorse and contribute to its evolution. It is guided by four founding principles: put patients first; support ethical research and innovation; ensure independence and ethical conduct; promote transparency and accountability. In 2025, the Framework was expanded to include a fifth principle: uphold responsible use of health data and technology. This reflects the growing importance of digital health and AI, and the need for ethics to evolve alongside innovation. Article content Article content Article content Article content Contacts Article content Media contacts Article content Article content

Headed to the beach for a swim? Here's what you should know before you go
Headed to the beach for a swim? Here's what you should know before you go

CBC

time5 hours ago

  • CBC

Headed to the beach for a swim? Here's what you should know before you go

Your guide to swimming in Ontario lakes this summer 2 hours ago Duration 2:28 Social Sharing When you think of beach cities, Toronto may not be the first to come to mind. Sure, we're on the lake, and yes, we have the Beaches, but on a hot day, many would turn their nose up at idea of taking a dip in the lake. But Toronto's beaches are some of the cleanest swimming areas in the world, according to Gregary Ford, vice-president of Swim Drink Fish Canada. The non-profit organization runs Canada's Blue Flag program, an international eco-certification awarded to beaches and marinas. "There's a stigma from the past that persists today about Lake Ontario. But we have clean, beautiful, amazing locations that people can cool off," he told CBC Toronto. "They are something that we're really fortunate to have here in Ontario." So if you're debating taking a swim in the lake this year or planning a beach day, here's what experts say you should consider before jumping into the water. Best practices Checking water quality data before you get into the water is the first and most important thing you should do, says Ford. "Water quality changes just like the weather does. It changes very quickly," he said. The status of Toronto's major beaches is posted on the city's website daily and includes details about when samples were last collected and how much E. coli was traced. There's usually some level of bacteria in the water but that shouldn't be an automatic red flag, says Mitch Bechtel. An open water swimmer, Bechtel developed Open Water Data, a website that shows detailed information about different swimming locations. "There's always some amount of bacteria. It's not a fresh-filtered water source. And it's OK that there's some bacteria in our bodies," he said. "What's interesting is that different regions have different thresholds that they consider safe or not… Ontario specifically is actually very strict, so when they say something is [has] passed, that's typically passed anywhere else in the world." Aside from checking for test results, best practice is to stay ashore after rainfall for 24 to 48 hours to avoid any wastewater runoff, Ford says. Additionally, if you see any birds or animals in water, stay clear of them, Bechtel said, because they "might be doing their thing in the water." Information on water quality tests can also be found on apps such as Swim, Drink, Fish's Swim Guide or in-person, lakeside, based on the flag on the lifeguard post.. Location, location, location This year, seven Toronto beaches received a Blue Flag designation. The international award is doled out worldwide to locations that demonstrate exceptional water quality and environmental management. The blue flag can be seen on world-class shores in Italy, Brazil and beyond. This summer, these seven Toronto beaches made the Blue Flag list: Gibraltar Point. Ward's Island Beach. Hanlan's Point. Cherry Beach. Kew-Balmy Beach. Woodbine Beach. Bluffer's Beach. Those locations tend to be a lot cleaner than others for two main reasons, Ford said. Not only are they away from the inner harbour, where water doesn't flush away as much, but they're also farther away from combined sewers, where stormwater mixes with wastewater and can spill into the lake after it rains. Toronto's west-end beaches aren't as lucky. "A good number of those combined sewers are in the Western Beaches area along the Humber River and emptying into Humber Bay," Ford said. "They are good quality beaches, and you can check the water quality for those beaches before you go out." Bechtel says conditions have vastly improved in recent decades after the city made improvements to its waterway and sewer systems.

Crohn's Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight
Crohn's Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight

Globe and Mail

timea day ago

  • Globe and Mail

Crohn's Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Crohn's Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Crohn's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Crohn's Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn's Disease Market. Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD). Some of the key takeaways from the Crohn's Disease Pipeline Report: Companies across the globe are diligently working toward developing novel Crohn's Disease treatment therapies with a considerable amount of success over the years. Crohn's Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn's Disease treatment Emerging Crohn's Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn's Disease market in the coming years. In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), after receiving FDA approval in December 2024. STEQEYMA is authorized for the same indications as STELARA, ensuring reliable treatment options for both patients and healthcare providers. In March 2025, Johnson & Johnson announced that the FDA has approved TREMFYA® (guselkumab), making it the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition affecting the gastrointestinal tract. In February 2025, Eli Lilly shared findings from the VIVID-2 open-label extension study at the Crohn's and Colitis Congress (CCC), revealing that most patients with moderately-to-severely active Crohn's disease treated continuously with OMVOH for two years achieved sustained clinical and endoscopic outcomes, including 43.8% of patients who had previously failed biologic therapies. In January 2025, The FDA approved OMVOH (mirikizumab) for Crohn's disease, reinforcing the role of IL-23 inhibitors. Demonstrating robust long-term effectiveness, OMVOH is also under investigation for use in pediatric patients, potentially fulfilling a critical unmet need in this group. Crohn's Disease Overview Crohn's Disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, most commonly affecting the small intestine and the beginning of the colon. It can lead to symptoms such as abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. The exact cause is unknown but is believed to involve an abnormal immune response, genetics, and environmental factors. Crohn's can affect any part of the gastrointestinal tract and may lead to complications like strictures, fistulas, or bowel obstruction. While there is no cure, treatments including medications, dietary changes, and sometimes surgery can help manage symptoms and inflammation. Emerging Crohn's Disease Drugs Under Different Phases of Clinical Development Include: MORF 057: Morphic Therapeutic OTL-104: Orchard Therapeutics TP-317: Thetis Pharmaceuticals AZD 7798: AstraZeneca IMU 856: Immunic CBP-307: Suzhou Connect Biopharmaceuticals PF-06651600: Pfizer Deucravacitinib: Bristol-Myers Squibb E6011: Eisai Inc Guselkumab: Janssen Pharmaceutical Mirikizumab: Eli Lilly and Company Filgotinib: Gilead Sciences RHB-104: RedHill Biopharma Ozanimod: Celgene Corporation Brazikumab: AstraZeneca Crohn's Disease Route of Administration Crohn's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Parenteral Intravenous Subcutaneous Topical Crohn's Disease Molecule Type Crohn's Disease Products have been categorized under various Molecule types, such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Crohn's Disease Pipeline Therapeutics Assessment Crohn's Disease Assessment by Product Type Crohn's Disease By Stage and Product Type Crohn's Disease Assessment by Route of Administration Crohn's Disease By Stage and Route of Administration Crohn's Disease Assessment by Molecule Type Crohn's Disease by Stage and Molecule Type DelveInsight's Crohn's Disease Report covers around 50+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Crohn's Disease product details are provided in the report. Download the Crohn's Disease pipeline report to learn more about the emerging Crohn's Disease therapies Some of the key companies in the Crohn's Disease Therapeutics Market include: Key companies developing therapies for Crohn's Disease are - Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others. Crohn's Disease Pipeline Analysis: The Crohn's Disease pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Crohn's Disease with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn's Disease Treatment. Crohn's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Crohn's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn's Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Crohn's Disease Pipeline Market Drivers High prevalence of Crohn's Disease, increase in Drug Development for Crohn's treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn's Disease Market. Crohn's Disease Pipeline Market Barriers However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn's Disease Market growth. Scope of Crohn's Disease Pipeline Drug Insight Coverage: Global Key Crohn's Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others Key Crohn's Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others Crohn's Disease Therapeutic Assessment: Crohn's Disease current marketed and Crohn's Disease emerging therapies Crohn's Disease Market Dynamics: Crohn's Disease market drivers and Crohn's Disease market barriers Table of Contents 1. Crohn's Disease Report Introduction 2. Crohn's Disease Executive Summary 3. Crohn's Disease Overview 4. Crohn's Disease- Analytical Perspective In-depth Commercial Assessment 5. Crohn's Disease Pipeline Therapeutics 6. Crohn's Disease Late Stage Products (Phase II/III) 7. Crohn's Disease Mid Stage Products (Phase II) 8. Crohn's Disease Early Stage Products (Phase I) 9. Crohn's Disease Preclinical Stage Products 10. Crohn's Disease Therapeutics Assessment 11. Crohn's Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Crohn's Disease Key Companies 14. Crohn's Disease Key Products 15. Crohn's Disease Unmet Needs 16 . Crohn's Disease Market Drivers and Barriers 17. Crohn's Disease Future Perspectives and Conclusion 18. Crohn's Disease Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store